qchron.com /1 week ago

Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...

Read source
seekingalpha.com /3 weeks ago

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease - Slides...

Read source
biopharmadive.com /2 weeks ago

T-Therapeutics reloads with a $133M megaround for bispecifics

The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.

Read source
newswire.com /1 month ago

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...

Read source
seekingalpha.com /4 weeks ago

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

Read source
qchron.com /3 weeks ago

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedi...

Read source
qchron.com /1 week ago

Antengene Presents Latest Preclinical Results of Novel Cos-TCE Platform AnTenGager‑D2 in Rapid Oral Abstract Presentatio...

SHANGHAI and HONG KONG, Nov. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedic...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Th...

Read source
bioengineer.org /1 month ago

Liquid Radioembolic Aims Radiation Directly at Brain Tumors Via Their Own Blood Supply

Mount Sinai and Johnson & Johnson will collaboratively evaluate an investigational liquid radioembolic that combines Iodine-131 with TRUFILL n-BCA to embolize and irradiate bra...

Read source
cafepharma.com /1 month ago

Tenpoint

Tenpoint Anonymous (not verified) Sun, 10/18/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/tenpoint.711562/ board...

Read source
biopharmadive.com /1 month ago

ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’

Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.

Read source
cafepharma.com /1 month ago

Tenpoint

Tenpoint Anonymous (not verified) Sat, 10/17/2026 - 10:13 field_thread_url https://cafepharma.com/boards/threads/tenpoint.711562/ board...

Read source
seekingalpha.com /6 days ago

Ideaya picks cancer drug candidate, targets human trial application in 2027

Read source
qchron.com /4 weeks ago

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Ca...

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars,...

Read source
genengnews.com /1 month ago

Antibody Blocks T Cell Infiltration and Limits Neurodegeneration in Alzheimer’s Mice

Researchers developed a potential antibody-based approach to reducing neurodegeneration in tauopathies, with studies showing that in a mouse Alzheimer’s model anti-CXCR3-treated an...

Read source
genengnews.com /4 days ago

Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach

ImmunoBrain's approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that...

Read source
pharmexec.com /1 month ago

<![CDATA[Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeut...

Read source
qchron.com /1 month ago

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager

Read source
qchron.com /1 month ago

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Nega...

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...

Read source
qchron.com /1 month ago

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 20...

SHANGHAI and HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedic...

Read source
newswire.com /6 days ago

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Re...

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...

Read source
electronicsforu.com /3 weeks ago

The Antenna Designed To Beat Heating Drift In Cancer Therapy

A new antenna aims to beat heating drift during cancer therapy by maintaining stable microwave power delivery. One way to assist cancer treatment can be done through heating up the...

Read source
genengnews.com /1 week ago

Therapeutic Immune Manipulation

Next-generation immunotherapy exploits diverse immune populations to address the challenges that CAR T-cell therapy faces. The post Therapeutic Immune Manipulation appeared first o...

Read source
blavity.com /1 week ago

Targeted Therapy Sac-TMT Could Change The Future Of Endometrial Cancer Treatment

For people whose endometrial cancer returns after treatment, finding another effective option can be difficult.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.